Stay updated with breaking news from Genome Aggregation Database. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Cyprium Therapeutics, Inc. ("Cyprium"), a Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress") partner company, with support from its licensing...
Fortress Biotech and Cyprium Therapeutics Announce Positive Clinical Data for CUTX-101, Copper Histidinate, Presented at 2021 American Academy of Pediatrics National Conference & Exhibition - read this article along with other careers information, tips and advice on BioSpace
.jpg)
Study explores how human ACE2 variants can modify SARS-CoV-2 binding A recent tour-de-force study by researchers from the United Kingdom reveals variants of the human angiotensin-converting enzyme 2 (ACE2) that can improve or decrease binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – including two variants with distinct population distributions showing an enhanced affinity for viral spike glycoprotein. This research paper is currently available on the bioRxiv* preprint server while the article undergoes peer review. Since the start of the coronavirus disease 201...
Amazon Web Services doubles down on genomics Neil Versel, Genomeweb Getty Images Amazon Web Services has been expanding its reach into genomics and continues to grow in areas like molecular diagnostics through new initiatives. As might be expected of one of the world's three largest commercial cloud platforms, AWS counts some well-known names in the genomics and bioinformatics world among its customers. "Over the past 15 years, AWS has helped remove the undifferentiated heavy lifting so that customers are able to figure out what's the differentiating value for them," Wilson To, AWS global hea...
Our six dermatology products are marketed by our partner company, Journey Medical Corporation (“Journey”). Our products generated net revenues of $44.5 million for full-year 2020, compared to full-year 2019 net revenues of $34.9 million, representing growth of 28%. Our products generated $13.7 million in revenues in the fourth quarter of 2020, compared to $11.1 million in the fourth quarter of 2019, representing growth of 23%. While we generated revenue growth year-over-year in 2020, sales of our products were impacted by the COVID-19 pandemic, which caused a temporary supply shortage and...